This is followed by in vitro and in vivo targeting of XIAP in breast cancer cells using specific XIAP inhibitor, embelin, either alone or in combination with PI3-kinase/AKT inhibitor, LY294002 to assess cell viability, apoptosis and xenograft tumor regression. The gene discussed is AKT1; the disease is breast cancer.